Dénes B
Central Veterinary Institute, Budapest, Hungary.
Acta Vet Hung. 1997;45(1):33-43.
To reduce the economic losses caused by Brucella abortus infection under the conditions of nomadic cattle breeding, more than half million cattle over 3 months of age (excluding male animals) were immunised with the B. melitensis Rev.1 vaccine in 7 provinces of Mongolia in the first year of a programme (1987). In the second year, only heifer calves over 3 months of age, yearling animals not vaccinated in the first year, as well as heifers over 2 years of age and cows were vaccinated. The vaccine was administered subcutaneously at a dose of 5 x 10(9) viable organisms. In co-operatives that had used the B. abortus B19 vaccine, the existing vaccination programme was maintained, and all cattle over 3 months of age (except male animals) were vaccinated with a dose of 5 x 10(10) viable organisms, using the same vaccination programme as in herds immunised with the Rev.1 vaccine. Before vaccination, two serological tests were carried out at an interval of 20-25 days to determine the incidence of Brucella infection. Serum samples were tested by the Rose Bengal test (RBT), serum agglutination test (SAT) and complement fixation test (CFT). An infection rate of 3.8-35% was found in the herds tested. Animals serologically positive for brucellosis were removed from the herds. Fifteen to 21 days after vaccination, blood samples were taken from 10% of the animals in all immunised herds. The serum samples were tested by SAT and CFT to check the seroconversion rate. In herds immunised with the Rev.1 vaccine 90% of the cows and 92.7% of the heifers were seropositive, while the seropositivity rate of B19-vaccinated cows and heifers was 68.8% and 89.7%, respectively. The serological status of the vaccinated animals was checked not only immediately after vaccination but also 12 months thereafter (in B19-vaccinated cows also 24 months after vaccination). After Rev.1 vaccination, antibodies were present in 7% of the cows, 4.6% of the 3-year-old heifers, 3.1% of the 2-year-old heifers, and 1.6% of the 1-year-old animals. By comparison, 13.2% of the cows vaccinated with the B. abortus B19 vaccine were serologically positive 2 years after immunisation. As regards the B19-vaccinated heifers, 7.9%, 5% and 2.7% of the 3-year-old, 2-year-old and 1-year-old animals, respectively, were serologically positive even 12 months after vaccination.
为减少游牧养牛条件下牛种布鲁氏菌感染造成的经济损失,在该项目的第一年(1987年),蒙古国7个省超过50万头3月龄以上的牛(不包括雄性动物)用羊种布鲁氏菌Rev.1疫苗进行了免疫接种。第二年,仅对3月龄以上的小母牛犊、第一年未接种疫苗的周岁动物以及2岁以上的小母牛和母牛进行了接种。疫苗通过皮下注射,剂量为5×10⁹个活菌体。在曾使用牛种布鲁氏菌B19疫苗的合作社中,维持现有的疫苗接种计划,所有3月龄以上的牛(雄性动物除外)均接种5×10¹⁰个活菌体的剂量,采用与用Rev.1疫苗免疫的畜群相同的接种程序。在接种疫苗前,每隔20 - 25天进行两次血清学检测,以确定布鲁氏菌感染的发生率。血清样本通过玫瑰红试验(RBT)、血清凝集试验(SAT)和补体结合试验(CFT)进行检测。在所检测的畜群中发现感染率为3.8% - 35%。血清学检测布鲁氏菌病呈阳性的动物被从畜群中剔除。接种疫苗15至21天后,从所有免疫畜群中10%的动物采集血样。血清样本通过SAT和CFT检测,以检查血清转化率。在用Rev.1疫苗免疫的畜群中,90%的母牛和92.7%的小母牛血清呈阳性,而接种B19疫苗的母牛和小母牛的血清阳性率分别为68.8%和89.7%。对接种动物的血清学状况不仅在接种后立即进行检查,而且在之后12个月(接种B19疫苗的母牛在接种后24个月也进行检查)。接种Rev.1疫苗后,7%的母牛、4.6%的3岁小母牛、3.1%的2岁小母牛和1.6%的1岁动物体内存在抗体。相比之下,接种牛种布鲁氏菌B19疫苗的母牛在免疫后2年血清学检测呈阳性的比例为13.2%。至于接种B19疫苗的小母牛,即使在接种后12个月,3岁、2岁和1岁动物的血清学阳性率分别为7.9%、5%和2.7%。